Shares of ArriVent BioPharma, Inc. (AVBP) have gained 29.8% over the past four weeks to close the last trading session at $24.36, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $31 indicates a potential upside of 27.3%. The average comprises five short-term price targets ranging from a low of $25 to a high of $35, with a standard deviation of $4.69. While the lowest estimate in ...